These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 27977392)

  • 1. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
    Mancia G; Cannon CP; Tikkanen I; Zeller C; Ley L; Woerle HJ; Broedl UC; Johansen OE
    Hypertension; 2016 Dec; 68(6):1355-1364. PubMed ID: 27977392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
    Ferdinand KC; Izzo JL; Lee J; Meng L; George J; Salsali A; Seman L
    Circulation; 2019 Apr; 139(18):2098-2109. PubMed ID: 30786754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.
    Chilton R; Tikkanen I; Hehnke U; Woerle HJ; Johansen OE
    Diabetes Obes Metab; 2017 Nov; 19(11):1620-1624. PubMed ID: 28387058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
    Tikkanen I; Narko K; Zeller C; Green A; Salsali A; Broedl UC; Woerle HJ;
    Diabetes Care; 2015 Mar; 38(3):420-8. PubMed ID: 25271206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
    Chilton R; Tikkanen I; Cannon CP; Crowe S; Woerle HJ; Broedl UC; Johansen OE
    Diabetes Obes Metab; 2015 Dec; 17(12):1180-93. PubMed ID: 26343814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis from the EMPA-REG OUTCOME
    Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
    Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Ferreira JP; Fitchett D; Ofstad AP; Kraus BJ; Wanner C; Zwiener I; Zinman B; Lauer S; George JT; Rossignol P; Zannad F
    Am J Hypertens; 2020 Dec; 33(12):1092-1101. PubMed ID: 32369546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
    Luque Otero M; Martell Claros N;
    Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
    Zinman B; Inzucchi SE; Lachin JM; Wanner C; Fitchett D; Kohler S; Mattheus M; Woerle HJ; Broedl UC; Johansen OE; Albers GW; Diener HC;
    Stroke; 2017 May; 48(5):1218-1225. PubMed ID: 28386035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study.
    Kario K; Okada K; Kato M; Nishizawa M; Yoshida T; Asano T; Uchiyama K; Niijima Y; Katsuya T; Urata H; Osuga JI; Fujiwara T; Yamazaki S; Tomitani N; Kanegae H
    Circulation; 2019 Apr; 139(18):2089-2097. PubMed ID: 30586745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus.
    Ferdinand KC; Seman L; Salsali A
    Curr Med Res Opin; 2018 Feb; 34(2):361-367. PubMed ID: 29139301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
    Scheen AJ
    Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.